Blockchain Registration Transaction Record

Clene Inc. Presents New Long-Term CNM-Au8 Treatment Results at European ALS Meeting

Clene Inc. presents new long-term CNM-Au8 treatment results for survival and neurofilament light levels from the HEALEY ALS Platform Trial open label extension at the European Network for the Cure of ALS meeting. The data highlights up to 42 months of survival follow-up and 76 weeks of long-term NfL biomarker results, showing a 28% reduction in biomarker NfL levels.

This news matters because it provides clinical evidence of the potential of CNM-Au8 as a treatment for ALS. The long-term improved survival results and reduction in neurofilament levels offer hope for patients with neurodegenerative diseases, including ALS, Parkinson’s, and multiple sclerosis.